BACKGROUND: Recent cancer survival trends among American Indian and Alaska Native (AN) people are not well understood; survival has not been reported among AN people since 2001. METHODS: This study examined cause-specific survival among AN cancer patients for lung, colorectal, female breast, prostate, and kidney cancers. It evaluated whether survival differed between cancers diagnosed in 1992-2002 (the earlier period) and cancers diagnosed in 2003-2013 (the later period) and by the age at diagnosis (<65 vs 65 years), stage at diagnosis (local or regional/distant/unknown), and sex. Kaplan-Meier and Cox proportional hazards models were used to estimate univariate and multivariate-adjusted cause-specific survival for each cancer. RESULTS: An improvement was observed in 5-year survival over time from lung cancer (hazard ratio [HR] for the later period vs the earlier period, 0.83; 95% confidence interval [CI], 0.72-0.97), and a marginally nonsignificant improvement was observed for colorectal cancer (HR, 0.81; 95% CI, 0.66-1.01). Site-specific differences in survival were observed by age and stage at diagnosis. CONCLUSIONS: This study presents the first data on cancer survival among AN people in almost 2 decades. During this time, AN people have experienced improvements in survival from lung and colorectal cancers. The reasons for these improvements may include increased access to care (including screening) as well as improvements in treatment. Improving cancer survival should be a priority for reducing the burden of cancer among AN people and eliminating cancer disparities.
INTRODUCTION
Cancer is a shared leading cause of morbidity and mortality across the diverse American Indian/Alaska Native (AI/AN) populations in the United States. 1 Nonetheless, there is wide variation in cancer incidence and mortality rates among AI/ AN populations by geographic region. [1] [2] [3] [4] Higher incidence and mortality rates from all cancers (combined) have been observed in the Northern and Southern Plains and in Alaska. 1 Variations also occur by cancer site; for example, several studies have reported that the incidence of tobacco-related cancers is higher among AI/AN populations with a higher prevalence of smoking (Southern Plains, Northern Plains, and Alaska 1 ) in comparison with AI/AN people in the Southwest, who smoke less. 5, 6 In addition, disparities exist between AI/AN and other racial/ethnic groups that inhabit the same geographic regions. For example, overall cancer incidence rates (all sites combined) equal or exceed those of non-Hispanic whites (NHWs) in both Alaska and the Northern Plains, whereas rates for AI/AN people in the Southwest are approximately half those of NHWs in the region. 1 Of concern, recent studies have suggested that the burden of cancer among AI/ AN people may be substantially higher than these incidence and mortality reports suggest because of racial misclassification. 7, 8 An alternative method for assessing the burden of cancer is an examination of survival. Previous reports have consistently shown that AI/AN populations have among the lowest survival rates of any racial/ethnic group. 9, 10 Differences in survival between AI/AN people and NHWs vary by cancer site, age, and stage at diagnosis; however, the risk of death may be up to 60% higher among AI/AN people than NHWs. 9 Improvements in cancer survival may indicate that the burden of cancer is decreasing in a population. 11 Yet, to our knowledge, no reports have systematically documented whether or how the cancer burden is changing among AI/AN people by examining trends in cancer survival over time.
This study examined cancer survival specifically among Alaska Native (AN) people. The Alaska Native Tumor Registry (ANTR) has provided population-based cancer surveillance for AN people since 1969, 12 yet survival in this group has not been reported since 2001. 13 Here, we document survival for the most common types of cancer among AN populations: female breast, colorectal, lung, prostate, and kidney cancers. 12 Our primary goal was to evaluate whether there were any improvements in survival over time by comparing survival in 2 time periods (1992-2003 and 2004-2013) . However, we also examined whether survival differed by age and stage at diagnosis as well as sex (where applicable).
MATERIALS AND METHODS

Study Population
Approximately 144,274 AI/AN people reside in Alaska
14
(individuals reporting an AI/AN identity alone or in combination with another racial identity), and they compose 19.5% of the Alaskan population. Almost 90% of AI/AN people living in Alaska identify as AN 15 ; therefore, hereafter we will refer to all AI/AN people resident in Alaska as AN people. Health care for AI/AN people residing in Alaska is provided by 32 regional tribal health organizations and the Alaska Native Tribal Health Consortium, which provides statewide services. There is 1 tribally managed tertiary health care facility in the state, located in Anchorage: the Alaska Native Medical Center (ANMC). Institutional review board approval and informed consent were not required for the current study because SEER Program data are publicly available, and all surveillance data were deidentified. Appropriate tribal review was obtained for publication of this study.
Data Sources
Cancer data were collected by the ANTR, which is a population-based central cancer registry that records information on AI/AN people who meet eligibility requirements for Indian Health Service benefits, who have been diagnosed with cancer in Alaska since 1969, and who resided in Alaska at the time of diagnosis. The ANTR has been collecting cancer information according to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program standards since its inception, and it has been a full member of the SEER Program since 1999. According to standard ANTR casefinding practices, cases were ascertained through a variety of sources, including 1) hospital discharge diagnoses for tribal and nontribal health facilities in Alaska, 2) tumor registry and pathology files of the ANMC and other instate health care facilities, 3) linkage to the Alaska State Cancer Registry and the Washington State Cancer Registry, and 4) death certificates (<1% of cases were registered solely on the basis of information from a death certificate). For the purposes of this study, we report on cancers diagnosed between January 1, 1992, and December 31, 2013, because these were the dates for which we had cause-ofdeath data available.
Study Population
To ensure an adequate number of cases, this analysis focused on incident cases of (and deaths from) the 5 most common types of cancer diagnosed among AN people: female breast cancer (International Classification of Diseases for Oncology, Third Edition [ICD-O-3] anatomic site codes C50.0-C50.9); colon, rectum, and rectosigmoid junction cancer (ICD-O-3 codes C18.0-C20.9 and C26.0); lung cancer (ICD-O-3 codes C34.0-C34.9); prostate cancer (ICD-O-3 code C61.9); and kidney and renal pelvis cancer (ICD-O-3 codes C64.9 and C65.9). We did not define a minimum number of cases for inclusion in this analysis. All analyses were restricted to individuals with malignant disease (ICD-O-3 behavior code 3). Benign and in situ cases were excluded.
Study Outcomes
The primary outcome in this study was cancer-specific death, and it was defined as the primary cause of death being the specific cancer of interest (as defined previously). 16 Cause-specific survival analyses are one way to account for competing risks for cancer surveillance data when more specific information is not available. Causespecific analyses were deemed more appropriate than relative survival methods for this study because of the lack of racially specific life tables. Mortality data were provided by linkage to the National Death Index Plus, which is maintained by the National Center for Health Statistics.
Statistical Analysis
Differences in patient and clinical characteristics were assessed with the chi-square test. Kaplan-Meier methods were used to calculate univariate 5-year cause-specific survival; log-rank tests were used to formally assess differences. To assess time-period differences, we compared the first half of the study period (1992-2002) with the latter half of the study period (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . For prostate cancer only, we examined 1995-2013 because of changes in the SEER historic stage A variable for this cancer site. We also examined survival by selected patient characteristics, including sex (male vs female), age at diagnosis (<65 vs 65 years), and stage of disease at diagnosis. As is the convention for population-based cancer statistics derived from the central cancer registry, we used the SEER staging system to define the stage of disease at diagnosis (SEER historic stage A: local vs regional/distant/unknown). 17 Multivariable-adjusted Cox proportional hazards models 18 were used to characterize changes in survival by time period, and they were adjusted for the previously listed patient characteristics. The proportional hazards assumption was checked by the inclusion of an interaction variable in our model for each covariate and the log of survival time. In accordance with prevailing standards, survival analyses were restricted to first primary cancers, cases of known age, and those histologically confirmed and followed over time; cases that were identified solely on the basis of death certificates or autopsy reports were excluded. 16, 19 Patients who were still alive on December 31, 2013, or who had died of other causes were censored. The survival time was restricted to 60 months for all analyses to ensure an equal duration of follow-up. All statistical tests were 2-sided and were assessed at an a level of P < .05. Statistical analyses were conducted with standard modules of the Statistical Analysis System (version 9.4; SAS Institute, Cary, North Carolina).
RESULTS
Select demographic and clinical characteristics of AN people diagnosed with breast cancer (females only), colorectal cancer, lung cancer, prostate cancer (males only), and kidney cancer, stratified by the time period of diagnosis (1992-2002 and 2003-2013) , are given in Table 1 . The sex distribution among cases did not differ by time period for colorectal and kidney cancers; however, fewer lung cancer cases were diagnosed among females in the earlier period (1992-2002) than the later period (2003-2013). The mean age at diagnosis varied by cancer site but was lowest for female breast cancer (mean age at diagnosis, 56.0 years; standard deviation, 12.9 years) and highest for prostate cancer (mean age at diagnosis, 66.8 years; standard deviation, 10.4 years). The proportion of cancers diagnosed in each age group did not differ by time period for colorectal, kidney, and prostate cancers. Conversely, more lung and breast cancers were diagnosed among those 65 years and older in the later period (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) versus the earlier period (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) . The distribution of cancer stages at diagnosis differed by time period only for lung cancer, for which there was a higher proportion diagnosed at a distant stage in the later period versus the earlier period.
Changes in Survival Over Time
Results from the Cox proportional hazards models analyzing survival between time periods among AN people are given in Table 2 ; Figure 1 shows the corresponding Kaplan-Meier plots. In multivariable-adjusted Cox proportional hazard models, we observed a statistically significant improvement in 5-year survival only from lung cancer (hazard ratio [HR] 467 (170) 609 (166) 413 (58) 583 (51) 420 (343) 506 (374) 122 (13) 209 (15) 81 (27) 152 ( 
Interaction Analysis
We found statistically significant interactions of age, sex, and time period with survival time for colorectal and lung cancers. To examine these further, we stratified survival by age and stage for these cancer sites; the Kaplan-Meier plots for these analyses are given in Supporting Figure 1 . The change in the hazard over time was most evident for lung cancer.
DISCUSSION
This study examined cause-specific survival from the leading cancers (colorectal, female breast, lung, prostate, and kidney cancers) diagnosed among AN people in 1992-2013. Survival was lowest with lung cancer and highest with female breast cancer and prostate cancer. To address our primary question of whether cancer survival has changed over time among AN people, we compared survival between earlier (1992-2002) and later time periods (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . In these analyses, we observed a 17% decreased risk of death for lung cancer over time and a marginally nonsignificant 19% decreased risk for colorectal cancer after adjustments for sex, age, and stage at diagnosis. Survival from breast, prostate, and kidney cancers did not differ by time period. We also assessed survival by demographic and clinical characteristics. Within each cancer site, survival was typically higher among those with a younger age and an earlier stage at diagnosis. These data provide the first examination of cancer survival specifically among AN people since 2001, and they suggest that this population may be experiencing improvements in survival for at least 2 of the 5 leading cancers. Lung cancer and colorectal cancer are the third and second leading causes of cancer incidence and the first and second causes of cancer mortality among AN people, respectively. 12 Incidence rates for these cancers are 1.5 and 2.3 times higher among AN people than NHWs. 12 For these reasons, the observed improvements in survival from these cancers is of great importance in the effort to alleviate the burden of cancer and reduce disparities among AN people. We found that the risk of death from lung and colorectal cancers decreased by approximately 20% between the earlier and later time periods despite previous reports that observed no statistically significant change in the incidence of or mortality from these cancers over the past 45 years of surveillance. 12 The improvements in lung cancer survival that we observed mirror those reported for US NHW, black, and Asian populations in the SEER 9 registries over a similar time period. 20 Survival improvements were slightly lower (10%) for AN patients with colorectal cancer in comparison with NHWs. 20 In contrast, although we did not observe any improvements in survival from prostate or breast cancer among AN people, substantial reductions in the risk of death were observed for both cancer sites among US NHW, black, and Asian populations over a similar time period (52%-65% for prostate cancers and 40%-48% for female breast cancers). 20 The reasons for improved survival over time (or a lack thereof) likely differ by cancer site. Many factors may affect cancer survival, including changes in treatment effectiveness; health care utilization and access, including screening and diagnostic services; and the receipt of timely care. [21] [22] [23] [24] [25] [26] For example, there have been improvements in lung cancer treatments over the period of study, 27 which may have contributed to our improvements observed for this cancer site. Alternatively, increased access to screening may have contributed to our findings of increased survival among AN patients with colorectal cancer. Between 1993 and 2015, the proportion of AN people receiving screening increased from 25.3% to 74.4%, 28 in large part because of a concerted effort to promote screening within the Alaska Tribal Health System. Unfortunately, it is not known whether there has been a concurrent stage shift in diagnoses over the time period examined that could implicate screening in improvements in survival outcomes, although future research could use the ANTR database to examine this question. In contrast, we found no improvements in survival from breast cancer despite an increase in the reported prevalence of breast cancer screening mammography from 62.2% (1991) (1992) (1993) (1994) (1995) to 77.1% (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) among women aged 50 to 74 years. 29 Although we did not directly compare survival among AN people with survival among US whites, our data can be compared with previously published reports. Previous studies have demonstrated racial disparities in cause-specific and relative survival from many of the leading cancers, 9, 16, 30, 31 with AI/AN people experiencing lower survival than their US white counterparts. 16 Our data are in general agreement with results from these studies. Remarkably, even though the incidence of and mortality from lung cancer are 1.5 times higher among AN people versus US whites, survival from lung cancer was similar. Yet, survival from breast, prostate, and colorectal cancer was lower among AN people than that reported for AI/AN people combined as well as US whites. 16 There are several potential reasons for the observed disparities in survival between AN people and US whites. First, there may be differences in the stage at diagnosis between AN people and NHWs. A recent analysis of colorectal cancer cases showed no difference in the stage at diagnosis for colorectal cancers 32 ; however, this may not be true for all cancer sites. Second, there could be differences in the biological aggressiveness of tumors between AN people and US whites, as has been suggested for black men and prostate cancer. 33, 34 Whether this is true for these cancer sites among AN people is unknown. Third, cancer treatments may not be as effective among AN people as among their US white counterparts. AI/AN and other minority populations are vastly underrepresented in clinical trials of cancer therapeutics, 35 and it is unknown whether standard therapies have the same efficacy among AN people as observed in these trials. 36 Finally, there may be differences in access to and delivery of care throughout the Alaska Tribal Health System that could affect cancer survival. Many cancer patients must travel long distances to receive care at the ANMC, located in Anchorage, which is the only tertiary tribal health care center in the state and provides cancer care to the majority of AN cancer patients. Further research is necessary to understand what factors, or combination thereof, may contribute to lower cancer survival among AN people. This is the first study in more than 16 years to examine cancer survival specifically among AN people. 13 To do this, we used data from a high-quality, population-based SEER registry, the ANTR. Yet, the study has several limitations that warrant consideration. Because the AN population is small, the numbers of cancers as well as cancer deaths were low. For this reason, we chose to focus our investigation on the 5 leading cancers: breast cancer, lung cancer, colorectal cancer, prostate cancer, and kidney cancer. Still, the relatively small number of cases available for study may have diminished our ability to detect a true change in survival over time. To maximize the number of cases in each time period, we compared data for 1992-2002 and 2003-2013; however, improvements in cancer treatment and survival may have occurred within each 12-year period. Because of these small case counts and as with any study conducted among small populations, a sparse data bias may also be a concern.
37 Five-year survival has been criticized as a metric of success against the burden of cancer because of the potential for a lead-time bias, a length bias, and/or overdiagnosis as a result of screening to perhaps create the appearance of an improvement where none truly exists. 38 Reductions in mortality rates have been proposed as a more suitable alternative; however, statistically significant trends in incidence and mortality rates can be hard to detect in small populations. Furthermore, these metrics may be affected by problems with racial misclassification in AI/AN populations. 8 It is possible that such misclassification of AI/AN race may have resulted in an underestimation of case counts in this population. However, racial misclassification has been shown to be lower in Alaska surveillance data in comparison with other Indian Health Service regions. 8 It is also possible that survival may have been affected by factors other than the covariates examined herein, such as comorbidities or access to cancer care. Unfortunately, these particular variables were not collected by the registry, and so we were unable to evaluate their potential impact on survival. Finally, cause-specific survival, particularly with a narrow definition of cancer death, as used herein, may overestimate survival 39 ; therefore, it is possible that true survival among AN people may be lower than the survival estimated herein.
In this study, we examined survival from the 5 leading cancers among AN people. We observed increases in survival of up to 20% for lung and colorectal cancers; however, there were no changes in survival over time for cancers of the breast, prostate, or kidney. Because of the known disparities for many of these cancer sites (lung, colorectal, and kidney) in comparison with US whites, comprehensive programs to prevent, screen, and treat cancer successfully among AN people are warranted.
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